In conclusion, our meta‐analysis based on 13 studies including more than 7600 patients, indicates a slight superiority of anti‐PD1 antibodies over anti‐PD‐L1 inhibitors when used in combination with chemotherapy as first‐line therapy for metastatic NSCLC patients; as monotherapy, both ICI strategies appear to be similar. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.